Company
Headquarters: Taichung, Taiwan
Employees: 19
CEO: Dr. Yung-Shun Wen Ph.D.
TW$9.29 Billion
TWD as of July 1, 2025
US$317.1 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Alar Pharmaceuticals Inc. operates as a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which primarily include opioid use disorder, chronic pain, and major depressive disorder. The company is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid addiction; and ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. The company was founded in 2016 and is based in Taichung, Taiwan.
Alar Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: TWSE: 6785 wb_incandescent